Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Tuesday, April 21, 2015

BrainStorm Cell Therapeutics Inc. Says Stem Cell Drug Benefits ALS Patients in Mid-Stage Trial

BrainStorm's NurOwnA Demonstrates a Statistically Significant Effect in ALS Patients Phase 2a Results and New Analyses Presented at American Academy of Neurology /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwnA in amyotrophic lateral sclerosis at a poster session today at the American Academy of Neurology annual meeting, taking place in Among the new results is a piecewise linear regression analysis of all subjects who received intrathecal administration in the phase 2a study and the prior phase 1/2 study.
http://ift.tt/1aO0jae

No comments:

Post a Comment

Popular Stem Cell Roundup Posts